imagen laboratorio

News and Events

News

SunRock is pleased to share a new publication in Molecular Oncology highlighting the potential of SRB2 in pancreatic ductal adenocarcinoma

SRB2 is a humanized monoclonal #antibody developed by SunRock Biopharma, S.L targeting #CCR9. 🎯 This study demonstrates the efficacy of SRB2…

La compostelana SunRock y el Instituto de Oncología del Vall d’Hebron reciben 1,8 millones de euros de la Agencia Estatal de Investigación para el desarrollo de nuevos anticuerpos en el tratamiento del cáncer de ovario

El consorcio integrado por SunRock Biopharma, con sede en el Biopolo Sionlla, y por VHIO lidera el proyecto OVERCAD,…

SunRock Biopharma will be giving an oral presentation on its anti-CCR9 antibody for IBD in ECCO25, Berlin.

SunRock’s communication has been selected for oral presentation at the 20th Congress of ECCO, February 19-22, 2025, Berlin, Germany. DOP065 SRB1:…

Events

SunRock Biopharma, S.L will be attending the BIOInternational 2025 in Boston from 16-19 June

We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…

SunRock Biopharma, S.L will be attending the BIOEquity 2025 in Bruges from 12-14 May

We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…

SunRock Biopharma, S.L will be attending the BIOEurope Spring 2025 in Milan from 17-19 March

We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…

SunRock Biopharma will be attending the 20th Congress of ECCO European Crohn’ and Colitis Organisation in Berlin from 19-22 February

We are a hashtag#biotech company with a pipeline of therapeutic hashtag#antibodies for the treatment of hashtag#inflammatory hashtag#bowel hashtag#disease. Are you attending…

Projects

OVERCAD

IMPANC

TRADBI

Bonos de Innovación GAIN

DIAGBI

Itrapsens

Innovation Plan

Fartusomin

BiAbCan

Axencia Galega de Innovación